Ketek and Phenobarbital Sodium
Determining the interaction of Ketek and Phenobarbital Sodium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:PHENobarbital may significantly reduce the blood levels of telithromycin, which may make the medication less effective in treating your infection. Telithromycin should generally not be used during or within two weeks of taking PHENobarbital. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme. When telithromycin was given with the potent CYP450 3A4 inducer rifampin in repeated doses, telithromycin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased on average by 79% and 86%, respectively. A similar interaction is expected with other potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, mitotane, phenytoin, phenobarbital, rifabutin, rifapentine and St. John's wort, potentially resulting in subtherapeutic levels of telithromycin and loss of effect. Enzyme activities usually return to normal 14 days after discontinuation of the inducing agent.
MANAGEMENT: Telithromycin should not be used during or within 2 weeks after discontinuation of treatment with a potent CYP450 3A4 inducer.
- "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals, Bridgewater, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm." ([2001]):
Generic Name: phenobarbital
Brand name: Solfoton, Luminal
Synonyms: Phenobarbital, PHENobarbital
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ketek-Phenobarbital Sodium Injection
- Ketek-Phenobarbital Tablets
- Ketek-Phenobarbital with Belladonna Alkaloids Elixir
- Ketek-Phenohytro
- Ketek-Phenohytro Elixir
- Ketek-Phenoxybenzamine
- Phenobarbital Sodium-Ketek Pak
- Phenobarbital Sodium-Ketocon
- Phenobarbital Sodium-Ketoconazole
- Phenobarbital Sodium-Ketoconazole (Systemic)
- Phenobarbital Sodium-Ketoconazole and Hydrocortisone
- Phenobarbital Sodium-Ketoconazole Tablets